News

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec

October

Oct.30, 2026 Notice
Notice Regarding Interim Dividend for the Fiscal Year Ending March 31, 2027
Oct.30, 2026 Release
(Correction and Correction of Numerical Data) Notice Regarding Partial Correction to “Notice of Revisions to Earnings Forecasts and Dividend Forecasts (Dividend Increase)”
Oct.29, 2026 Release
Notice Regarding Interim Dividend
Oct.29, 2026 Release
Notice of Revisions to Earnings Forecasts and Dividend Forecasts (Dividend Increase)
Oct.29, 2026 Release
Notice Regarding the Execution of a Share Transfer Agreement with Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. for the Transfer of the Generic Drug Business in China
Oct.29, 2026 Notice
Financial Results and Supplement for FY2026 2Q
Oct.29, 2026 Notice
Presentation Materials for FY2026 2Q Financial Results
Oct.21, 2026 Release
Shionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
Oct.21, 2026 Release
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
Oct.21, 2026 Release
IDWeek 2026: New Exploratory Analyses Evaluate XOCOVA® (ensitrelvir) Following COVID-19 Exposure, Including Breakthrough Infections and Infection Present at Baseline
Oct.07, 2026 Release
Results of Third-Phase Activities in Kenya and Ghana under the “Mother to Mother SHIONOGI Project”
Oct.06, 2026 Release
Transfer of Marketing Authorization and Sales Operations for the Allergen Immunotherapy treatment Actair® in Japan
Oct.05, 2026 Release
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
Oct.05, 2026 Notice
Shionogi Announces Investment in Celaid Therapeutics, Inc. through Its Corporate Venture Capital Activities

September

Sep.28, 2026 Release
Shionogi Announces European Commission Approval of Zokovea® (ensitrelvir) for Post-Exposure Prophylaxis of COVID-19
Sep.25, 2026 Release
Notice Regarding Relocation of the Tokyo Nihonbashi Office
Sep.16, 2026 Release
COVGOZE® for Intramuscular Injection (JN.1-adapted), Recombinant Protein COVID-19 Vaccine, Receives Partial Change Approval in Japan
Sep.16, 2026 Release
Notice Regarding Approval of an Additional Dosage and Administration of VTAMA® Cream for Pediatric Atopic Dermatitis (Under Age12) in Japan
Sep.10, 2026 Release
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
Sep.09, 2026 Release
StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in Patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke
Sep.07, 2026 Release
Approval for Cefiderocol in Australia

August

Aug.28, 2026 Release
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
Aug.26, 2026 Release
Execution of an Agreement to Terminate the Commercialization Agreement with SUSMED Co., Ltd. for a Digital Therapeutic Application for Insomnia
Aug.05, 2026 Notice
Notice transcript of FY 2026 1Q financial result meeting
Aug.03, 2026 Notice
Financial Results and supplement for FY2026 1Q
Aug.03, 2026 Notice
Presentation Materials for FY2026 1Q financial results

July

Jul.29, 2026 Release
Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*
Jul.23, 2026 Release
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Jul.17, 2026 Release
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria Submission intends to address a critical therapeutic gap for vulnerable young patients facing drug-resistant pathogens
Jul.13, 2026 Release
Notice of Execution of a Joint Research Agreement with Nagasaki University and MMV for the Discovery of a Novel Malaria Prevention Drug, and Selection for Funding by the GHIT Fund

June

Jun.24, 2026 Notice
Update for Actions to Achieve Management that is Conscious of Capital Costs and Stock Prices
Jun.24, 2026 Release
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Jun.19, 2026 Release
Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA® to Treat COVID-19
Jun.18, 2026 Release
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
Jun.12, 2026 Notice
Shionogi Announces Investment in Dioseve, Inc. through Its CVC Activities
Jun.05, 2026 Release
ENDEAVORRIDE® Digital Therapeutic App for Adjunctive Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder (ADHD) Launched in Japan
Jun.01, 2026 Notice
(Corrections) Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
Jun.01, 2026 Release
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

May

May.29, 2026 Release
Notice Regarding Approval of Naldemedine for Opioid-Induced Constipation in China
May.26, 2026 Notice
Notice of Convocation of the 161st Annual General Meeting of Shareholders
May.19, 2026 Release
Positive Interim Analysis Results from Phase 3 Clinical Trial of Tapinarof Cream 0.5%, Aryl Hydrocarbon Receptor (AhR) Modulating Agent, in Infant Patients with Atopic Dermatitis in Japan
May.15, 2026 Notice
Notice transcript of FY 2025 financial result meeting
May.14, 2026 Release
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
May.12, 2026 Notice
Financial Results and Supplement for FY2025
May.12, 2026 Notice
Presentation Materials for FY2025 financial results

April

Apr.28, 2026 Notice
Shionogi Joins the World Economic Forum and Signs the Davos Compact on Antimicrobial Resistance - Contributing to the resolution of global healthcare challenges, including AMR, through international collaboration-
Apr.27, 2026 Release
Notice Regarding the Absorption-Type Merger of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary
Apr.27, 2026 Release
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Apr.15, 2026 Notice
Shionogi Announces Investment in Restore Vision Inc. through Its CVC Activities
Apr.10, 2026 Release
Shionogi Selected as a “DX Stock 2026”
Apr.08, 2026 Release
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Apr.08, 2026 Release
ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infections
Apr.02, 2026 Release
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Apr.01, 2026 Release
GSK, Pfizer and Shionogi complete changes to ViiV Healthcare shareholding
Apr.01, 2026 Release
SHIONOGI Group’s Efforts to Address AMR Highly Rated -Ranked No. 2 Among Global R&D-Based Pharmaceutical Companies in the Antimicrobial Resistance Benchmark 2026-

March

Mar.27, 2026 Release
Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd
Mar.24, 2026 Release
Notice Regarding the Consolidation of Shionogi‑Apnimed Sleep Science, LLC as a Subsidiary of Shionogi
Mar.23, 2026 Release
Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
Mar.23, 2026 Release
Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA® (Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19.
Mar.19, 2026 Release
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
Mar.19, 2026 Release
ZURZUVAE® Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan

February

Feb.27, 2026 Release
Application for Manufacturing and Marketing Approval of a New Lotion Formulation for the Atopic Dermatitis Treatment "CORECTIM®" in Japan
Feb.24, 2026 Release
Notice of the Candidate for Director
Feb.20, 2026 Release
Notice Regarding the Determination of the Basic Policy for the Absorption-Type Merger of TORII PHARMACEUTICAL Co., Ltd.
Feb.13, 2026 Release
Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective April 1, 2026)
Feb.09, 2026 Release
Shionogi Notes Torii Pharmaceutical’s Announcement on the Launch of YCANTH® topical solution 0.71% for the Treatment of Molluscum Contagiosum in Japan

January

Jan.30, 2026 Notice
Presentation Materials for FY2025 3Q financial results
Jan.30, 2026 Notice
Financial Results and supplement for FY2025 3Q
Jan.20, 2026 Release
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
Jan.19, 2026 Release
Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize
Jan.08, 2026 Release
Approval for Cefiderocol in China